These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35051553)

  • 1. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
    Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
    Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FMO1 Promotes Nonalcoholic Fatty Liver Disease Progression by Regulating PPARα Activation and Inducing Ferroptosis.
    Zou L; Shi Q; Li Y; Yuan Z; Peng L; Lu J; Zhu H; Ma J
    Discov Med; 2023 Aug; 35(177):612-622. PubMed ID: 37553313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
    Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRDX6 Promotes Fatty Acid Oxidation
    Shen W; Yang L; Yang Y; Wang P; Tao X; Shen Y; Wang S; Shen Y
    Antioxid Redox Signal; 2023 Jun; 38(16-18):1184-1200. PubMed ID: 36401357
    [No Abstract]   [Full Text] [Related]  

  • 5. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
    Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
    Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
    J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
    Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
    Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
    Xie L; Wen K; Li Q; Huang CC; Zhao JL; Zhao QH; Xiao YF; Guan XH; Qian YS; Gan L; Wang LF; Deng KY; Xin HB
    Int J Biol Sci; 2021; 17(15):4305-4315. PubMed ID: 34803499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferulic Acid Prevents Nonalcoholic Fatty Liver Disease by Promoting Fatty Acid Oxidation and Energy Expenditure in C57BL/6 Mice Fed a High-Fat Diet.
    Luo Z; Li M; Yang Q; Zhang Y; Liu F; Gong L; Han L; Wang M
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway.
    Liu X; Hu M; Ye C; Liao L; Ding C; Sun L; Liang J; Chen Y
    Chem Biol Interact; 2022 Dec; 368():110250. PubMed ID: 36347319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
    Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
    J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.
    Régnier M; Polizzi A; Smati S; Lukowicz C; Fougerat A; Lippi Y; Fouché E; Lasserre F; Naylies C; Bétoulières C; Barquissau V; Mouisel E; Bertrand-Michel J; Batut A; Saati TA; Canlet C; Tremblay-Franco M; Ellero-Simatos S; Langin D; Postic C; Wahli W; Loiseau N; Guillou H; Montagner A
    Sci Rep; 2020 Apr; 10(1):6489. PubMed ID: 32300166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fat mass and obesity-associated protein promotes liver steatosis by targeting PPARα.
    Wei X; Zhang J; Tang M; Wang X; Fan N; Peng Y
    Lipids Health Dis; 2022 Mar; 21(1):29. PubMed ID: 35282837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
    Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
    J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.